A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC).
Ravinder Clayton
Research Funding - Janssen Pharmaceutical ; Janssen Pharmaceuticals
Daniel Yick Chin Heng
Honoraria - Janssen Pharmaceutical ; Johnson & Johnson
Jackson S.Y. Wu
No relevant relationships to disclose
Rob Zielinski
No relevant relationships to disclose
Scott A. North
Honoraria - Janssen Pharmaceutical ; Johnson & Johnson
Urban Emmenegger
No relevant relationships to disclose
Sebastien J. Hotte
No relevant relationships to disclose
Humaid Obaid Al-Shamsi
No relevant relationships to disclose
Leo Chen
No relevant relationships to disclose
Bernhard J. Eigl
Honoraria - Janssen Pharmaceutical ; Janssen Pharmaceutical
Research Funding - Janssen Pharmaceutical